S&T-06 HIGH ABSOLUTE MONOCYTE COUNT PREDICTS POOR CLINICAL OUTCOME IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER TREATED WITH DOCETAXEL CHEMOTHERAPY

Poor Clinical Outcome ◽

Castration Resistant ◽

High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy

Annals of Surgical Oncology ◽

10.1245/s10434-016-5354-5 ◽

2016 ◽

Vol 23 (12) ◽

pp. 4115-4122 ◽

Cited By ~ 12

Author(s):

Keisuke Shigeta ◽

Takeo Kosaka ◽

Shigehisa Kitano ◽

Yota Yasumizu ◽

Yasumasa Miyazaki ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Outcome ◽

Monocyte Count ◽

Poor Clinical Outcome ◽

Castration Resistant ◽

Editorial Comment to High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy

International Journal of Urology ◽

10.1111/iju.12856 ◽

2015 ◽

Vol 22 (9) ◽

pp. 834-834

Author(s):

Robert J van Soest

Keyword(s):

Prostate Cancer ◽

Clinical Outcome ◽

Editorial Comment ◽

Neutrophil To Lymphocyte Ratio ◽

Poor Clinical Outcome ◽

Lymphocyte Ratio ◽

Castration Resistant ◽

High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy

International Journal of Urology ◽

10.1111/iju.12839 ◽

2015 ◽

Vol 22 (9) ◽

pp. 827-833 ◽

Cited By ~ 16

Author(s):

Akihisa Yao ◽

Takehiro Sejima ◽

Hideto Iwamoto ◽

Toshihiko Masago ◽

Shuichi Morizane ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Outcome ◽

Neutrophil To Lymphocyte Ratio ◽

Poor Clinical Outcome ◽

Lymphocyte Ratio ◽

Castration Resistant ◽

High neutrophil to lymphocyte ratio (NLR) persistence during enzalutamide to predict poor clinical outcome in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e16059 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e16059-e16059 ◽

Cited By ~ 1

Author(s):

Ugo De Giorgi ◽

Simon J. Crabb ◽

Robert J. Jones ◽

Orazio Caffo ◽

Tony Elliott ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Outcome ◽

Neutrophil To Lymphocyte Ratio ◽

Poor Clinical Outcome ◽

Lymphocyte Ratio ◽

Faculty Opinions recommendation of A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.3350956.3039058 ◽

2010 ◽

Author(s):

Yoshihiko Hirao ◽

Kiyohide Fujimoto

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant ◽

Transdermal Estradiol ◽

Re: Axel Heidenreich, David Pfister. Treatment Decisions for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel Chemotherapy: The Role of Cabazitaxel in the Continuum of Care. Eur Urol 2012;62:1201–4

European Urology ◽

10.1016/j.eururo.2013.03.056 ◽

2013 ◽

Vol 64 (3) ◽

pp. e62-e64

Author(s):

Sabine Brookman-May ◽

Bertrand Tombal ◽

Steven Joniau

Keyword(s):

Prostate Cancer ◽

Treatment Decisions ◽

Continuum Of Care ◽

Castration Resistant ◽

Docetaxel Chemotherapy ◽

The Continuum

Impact of metabolic syndrome on clinical outcome of castration resistant prostate cancer (CRPC) patients treated with abiraterone and enzalutamide

Annals of Oncology ◽

10.1093/annonc/mdx423.002 ◽

2017 ◽

Vol 28 ◽

pp. vi17

Author(s):

V. Conteduca ◽

O. Caffo ◽

L. Galli ◽

A. Maugeri ◽

E. Scarpi ◽

...

Keyword(s):

Prostate Cancer ◽

Metabolic Syndrome ◽

Clinical Outcome ◽

Serum Pre-Albumin Predicts the Clinical Outcome in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone

Journal of Cancer ◽

10.7150/jca.21134 ◽

2017 ◽

Vol 8 (17) ◽

pp. 3448-3455 ◽

Cited By ~ 8

Author(s):

Liancheng Fan ◽

Chenfei Chi ◽

Sanwei Guo ◽

Yanqing Wang ◽

Wen Cai ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Outcome ◽

Cancer Patients ◽

The Relationship Between Total Lesion Activity on 18F Choline Positron Emission Tomography-Computed Tomography and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Bone Metastases Treated with 223Radium

Cancer Biotherapy & Radiopharmaceuticals ◽

10.1089/cbr.2019.3188 ◽

2020 ◽

Vol 35 (6) ◽

pp. 398-403 ◽

Cited By ~ 3

Author(s):

Luca Filippi ◽

Pietro Basile ◽

Orazio Schillaci ◽

Oreste Bagni

Keyword(s):

Prostate Cancer ◽

Computed Tomography ◽

Positron Emission Tomography ◽

Clinical Outcome ◽

Bone Metastases ◽

Emission Tomography ◽

Castration Resistant ◽

Positron Emission ◽

The Relationship

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

European Urology ◽

10.1016/j.eururo.2014.10.027 ◽

2015 ◽

Vol 67 (4) ◽

pp. 795-802 ◽

Cited By ~ 110

Author(s):

Roberta Ferraldeschi ◽

Daniel Nava Rodrigues ◽

Ruth Riisnaes ◽

Susana Miranda ◽

Ines Figueiredo ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Outcome ◽

Abiraterone Acetate ◽

Protein Loss ◽

Pten Protein ◽